The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
The goal of this research study is to determine if DetectnetTM PET/CT scanning over several days can be used to deliver Lutathera in a safer manner. In this research, participants will be asked to complete a screening phase and possibly a dosimetry phase. The screening phase will require 2 visits. The dosimetry phase will also require 3 research visits.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
SPECT/CT will be performed after first cycle of Lutathera® treatment
PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
Standard of care administration of radioactive drug for PET/CT
University of Wisconsin - Madison
Madison, Wisconsin, United States
RECRUITINGCompare pre-therapy and post-therapy voxel-based dosimetry estimates
Absorbed doses to organs will be estimated using radiation dosimetry methods based on both multi-timepoint PET and multi-timepoint SPECT imaging. Mean dose estimates in units of Gy to the index tumor(s) and dose limiting organs (kidneys and bone marrow) will be compared between PET-based dosimetry and SPECT-based dosimetry. Using SPECT-based dosimetry as the gold standard truth, Bland-Altman analysis will be performed for each organ/tumor to compare PET-based dose estimates to SPECT-based estimates. Mean bias and 95% confidence intervals will be calculated.
Time frame: Baseline and 120 hours post-dose
Absorbed radiation doses
Absorbed radiation doses from 177Lu-DOTATATE in organs will be summarized with descriptive statistics.
Time frame: 1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 120 hours post-dose
Absorbed radiation doses of 64Cu-DOTATATE
Absorbed radiation doses of 177Lu-DOTATATE in organs using 64Cu-DOTATATE as an imagining surrogate will be summarized with descriptive statistics.
Time frame: 1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 120 hours post-dose
Compare 3D voxel-based versus model based dosimetry in participants receiving 177Lu_DOTATATE
Absorbed doses to organs will be estimated using radiation dosimetry methods based on multi-timepoint SPECT imaging. Mean dose estimates in units of Gy to the index tumor(s) and dose limiting organs (kidneys and bone marrow) will be compared between 3D voxel-based and model-based dosimetry methods. Using 3D voxel-based dosimetry as the gold standard truth, Bland-Altman analysis will be performed for each organ/tumor to compare 3D voxel-based to model-based methods. Mean bias and 95% confidence intervals will be calculated.
Time frame: Baseline and 120 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Standard of care administration of radioactive drug for PET/CT and SPECT/CT